Abstract Amino acid transport and protein synthesis are important steps of tumor growth. We investigated the time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and compared metabolic responses as measured with positron emission tomography (PET) with volume responses as revealed by magnetic resonance imaging (MR). A homogeneous population of 11 patients with progressive non-enhancing LGG was prospectively studied. Imaging was done at 6-months intervals starting six months, and in a second series starting three months after treatment initiation. F-18 fluoro-ethyl-Ltyrosine (FET) uptake was quantified with PET as metabolically active tumor volume, and was compared with the tumor volume on MR. Response was defined as C10% reduction of the initial tumor volume. Eight patients showed metabolic responses. Already 3 months after start of chemotherapy the active FET volumes decreased in 2 patients to a mean of 44% from baseline. First MR volume responses were noted at 6 months. Responders showed a volume reduction to 31 ± 23% (mean ± SD) from baseline for FET, and to 73 ± 26% for MR. The time to maximal volume reduction was 8.0 ± 4.4 months for FET, and 15.0 ± 3.0 months for MR. The initial metabolic response correlated with the best volume response on MR (Spearman Rank P = 0.011). Deactivation of amino acid transport represents an early indicator of chemotherapy response in LGG. Response assessment based on MR only has to be reconsidered. The time window obtained from PET may assist for individual treatment decisions in LGG patients.
Introduction
Chemotherapy represents a treatment option in low-grade glioma patients (LGG) [1] . This may be particularly important if tumors are not amenable to gross resection or irradiation. Several retrospective studies have shown that chemotherapy (either temozolomide or PCV regimen) was active in LGG. Using magnetic resonance (MR) imaging chemotherapy yielded response rates up to 61% [2] [3] [4] [5] [6] which were mainly determined by Macdonald's criteria [7] , although these criteria are not validated for LGG. The median time to reach a morphological response in the largest series was 12 months [4] . As many LGG grow very slowly the inhibition of tumor metabolism may be detected earlier than structural volume changes. Early identification of treatment response by molecular imaging may be promising. Positron emission tomography (PET) allows to quantitatively measure several biochemical and physiological alterations in brain tumors. Increased amino acid transport and protein synthesis represent essential and early steps of tumor growth [8] . In our present study we used PET with the radiolabeled amino acid analogue tyrosine (F-18 fluoro-ethyl-L-tyrosine, FET) to characterize metabolic responses in LGG patients treated with the alkylating agent temozolomide (TMZ).
Methods
Patients A homogeneous population of 11 patients (median age 34 years, range 23-49 years, 3 female and 8 male) with progressive supratentorial LGG WHO II consented to participate in our study (3 oligodendrogliomas, 4 fibrillary astrocytomas and 4 oligoastrocytomas [9] ). Progression was defined on MR as an increase in tumor size of [25% and/or clinical deterioration (according to the EORTC study protocol on low-grade gliomas, 22033-26033 [10] ), and occurred at a median of 27 months after the first tumor surgery (range 2-127 months). No patient had received previous radio-or chemotherapy. We included only patients which did not show any gadolinium enhancement on MR as the latter may be suggestive for transformation to malignant glioma. The clinical data are presented in Table 1 . Patients received 75 mg/m 2 TMZ per day over 3 weeks, followed by one week off (21q/28d = one cycle, according to EORTC protocol 22033-26033 [10] ). Patients were scheduled to receive 12 cycles of chemotherapy. TMZ chemotherapy was discontinued at the time of tumor progression or due to inacceptable side effects. Following the baseline scans the imaging protocol consisted of PET and MR scans at six-month intervals, starting after six cycles of chemotherapy in group A (n = 8). Due to the magnitude of PET responses observed at six months in group A the first follow-up scans in three subsequent patients (group B, Table 1 ) started after three cycles of chemotherapy. Further follow-up scans in group B patients were scheduled 9 and 15 months after initiation of treatment. Based on the clinical judgement several patients received more than 12 cycles (up to 24). The study protocol was approved by the local Ethical Committee. Written consent was obtained from all patients.
Imaging
MR imaging included standard sequences on a 1.5 Tesla Siemens Magnetom. Amino acid imaging with PET was done with F-18-fluoro-ethyl-L-tyrosine (FET). 3D PET data were acquired with a whole-body PET/CT Scanner (Discovery LS, GE Medical Systems, Waukesha, WI, USA, 14.6 cm axial field of view, in-plane resolution 7 mm). FET was intravenously administered as bolus injection of 140-250 MBq. FET uptake was measured on PET images acquired from 50 to 60 min after tracer injection [11] .
Data analysis
Quantification of PET and MR data was done using PMOD [12] on digitized images as described in detail in our recent publication [13] . For calculation of the MR tumor volume we used the FLAIR sequence which provides the best delineation between tumor and adjacent brain [3, 14] . Following manual outlining of the tumor boundaries the areas of all tumor containing MR slices were summed up to yield the whole tumor volume. For quantification of the FET PET data the cerebellum was used as reference region.
Regions of interest (ROI) covering the whole cerebellum were drawn for each slice. The ROI counts of all PET slices which contained the cerebellum were then averaged to produce the mean cerebellar FET uptake (counts). For tumors two measures were calculated. First, the 'active volume' (ccm) was quantified as the tumor volume containing pixels [110% of the mean cerebellar FET uptake. This threshold corresponds well to the visual impression of active LGG [13, 15] . Second, the tumor FET uptake (counts) of the active volume was normalized to the mean FET uptake of the cerebellum (T:CBL ratio, unit-less). This uptake ratio is routinely used in nuclear medicine, and is robust with regard to intra-and inter-individual comparisons. For the one patient who showed no active FET tumor volume (#10) the T:CBL ratio was calculated using the tumor area derived from the MR FLAIR images. As TMZ-induced reductions of FET uptake were better detectable by active volumes than by T:CBL ratios, we defined treatment response as a C10% reduction of the initial tumor volume (active PET, MR FLAIR) on at least two subsequent time points after the initiation of chemotherapy. Defining treatment response as a 20% volume reduction produced the same number of metabolic, but a lower number of MR responders. The Spearman rank test (SPSS, version 10.0.7) was applied to test whether baseline tumor FET uptake, or metabolic responses during treatment, were correlated with treatment response on MR.
Results
In total 172 cycles of TMZ were administered (mean 16, range 6-24 per patient). The initially scheduled TMZ dose could be maintained in 9 patients, in the two other patients the dose had to be reduced by 20% and 30% respectively due to hematotoxicity (CTCAE v3.0, grade 2 and 3). In group A 3 patients completed 4 follow-up PET-MR scans, 3 patients completed 3 scans, and 2 patients completed 1 scan. In group B each 1 patient completed 4, 3, and 2 follow-up scans.
Tumor volumes
At baseline a variable active FET tumor volume was found in 10/11 patients (range 6-273 ccm). This is line with earlier reports which describe a lack of increased amino acid uptake in a proportion of LGG [16] . The absolute numbers of the baseline active FET and MR volumes are presented in Table 1 . Overall 8/11 patients were metabolic responders. Among these only five patients also showed a MR volume response ( Table 1) . Examples of individual responses are presented in Figs. 1 and 2 . At three months 2/3 patients (group B, #1, 5) showed a substantially reduced active FET volume (38% and 49% of baseline volume), whereas no MR volume change was observed. In one patient the metabolic response persisted until 15 months (#5, Fig. 1c and bottom Fig. 2 ). At that time also a small volume response was noted on MR (90% of baseline). In group A patients (first followup study at six months) 6/8 patients showed a reduced active FET volume (range 7-71% of baseline volume). At that time 4/8 MR volume reductions were observed. The delay between FET and MR volume reductions is illustrated in Fig. 3 . Whereas the maximal reduction of the active FET volume was observed between 3 and 12 months (8.0 ± 4.4, mean ± SD), the delay to maximum MR volume reduction was 15.0 ± 3.0 months. The best FET response reached a mean of 31 ± 23% from baseline (Table 1) , whereas the best volume response on MR reached a mean of 73 ± 26% from baseline.
Uptake ratios
The range of baseline FET T:CBL ratios was 1.10-1.64 (Table 1 ). In responders the maximal reduction of FET uptake ratios was 76% from baseline. Similar to the active volume the maximal response of FET uptake ratios was reached until 12 months.
Response prediction
Before treatment neither the active tumor volume nor the uptake ratio predicted the response to TMZ chemotherapy (Spearman rank P [ 0.68). However, the FET volume response measured at the time of the first follow up study correlated with the best MR volume response obtained later during the course of chemotherapy (Spearman Rank 0.731, P = 0.01, Fig. 4 
Clinical follow up, tumor progression
A clinical benefit emerged for two patients which were seizure-free after four and six months of chemotherapy respectively. Those patients with PET and MR responses showed the longest progression-free survival (PFS; 38 ± 3 months). At the time of last follow up 3/8 metabolic responders were still free of progression. In patients without MR response variable PFS periods were noted (15 ± 8 months). 5/8 metabolic responders progressed 19 ± 7 months after initiation of chemotherapy. Four progressive patients underwent re-operation between 6 and 21 months after initiation of chemotherapy, which yielded unchanged histology (#8), anaplastic oligoastrocytoma WHO III (#5), anaplastic astrocytoma (#9), and glioblastoma WHO IV (#2). In those three patients with progression towards WHO grade III or IV a prominent increase particularly of the uptake ratio was observed (1.98, 1.37, 1.69 compared to an uptake ratio of 1.24, 1.24, 1.16 at best response). Also the active FET volume increased (28, 47, 23 ccm compared to 6, 3, 8 ccm at best response). This is examplified by Fig. 1c and bottom panel of Fig. 2 .
Discussion
LGG tend to grow slowly. A mean tumor diameter increase of 4.1 mm per year was reported in oligodendrogliomas or mixed gliomas on serial MR [17] . TMZ chemotherapy reversed this increase and led to an average tumor diameter decrease of 9.1 mm per year in one series [18] . The key finding of our study is that a substantial proportion of patients initially showing stable MR volumes are 'early' metabolic responders during chemotherapy, and that metabolic responses are more pronounced than MR volume responses. Of note none of the patients included in our series showed blood-brain barrier disruption as revealed by gadolinium enhanced MR. Interestingly, not only oligodendroglial tumors but also fibrillary astrocytomas showed metabolic responses, which preceded MR volume reductions by several months. These responses were particularly evident from the reduction of the active FET tumor volume. In contrast, the uptake indices (T:CBL ratios) in responders decreased only slightly. This suggests a decrease in tumor cell density, and indicates that the residual viable tumor has a metabolic activity similar to the untreated tumor, which is compatible with an unchanged histology and WHO tumor grade during chemotherapy. Discrepancies between changes in amino acid uptake (C-11 methionine) and MR volume reductions were also reported in pure oligodendrogliomas WHO II [15] . That study addressed the magnitude of metabolic and MR volume response after completion of 4-6 cycles of PCV chemotherapy, and also found that responses are more pronounced on metabolic compared to MR imaging. Various other treatment modalities also produced reductions of amino acid uptake in LGG (radio-chemotherapy [19] , external beam radiotherapy [20] , interstitial brachytherapy with I125-Iodine seeds [21] ). Extrapolating our data in responding patients toward earlier time points (Fig. 3) suggests that metabolic responses may be observed as early as one month after treatment initiation. Vice versa we also found that tumor progression was earlier evident on metabolic imaging compared with MR ( Fig. 1c and bottom  Fig. 2 ). Our data therefore underline the role of PET imaging with amino acids as a sensitive tool for early response assessment in LGG.
Upregulation of amino acid transporters in human astrocytomas can be demonstrated by immunohistochemistry and correlates with the WHO grade [22, 23] . In accordance, increased amino acid transport as measured in vivo with PET also correlates with the WHO grade of gliomas [24, 25] . The importance of amino acid transport for tumor growth is illustrated by experiments which show that specific transport inhibitors produce a rapid suppression of cell growth, and prolong survival of rats treated with C6 glioma cells [22] . Also successful chemotherapy with the alkylating agent TMZ decreases amino acid transport as shown in our study. As long as amino acid transport was deactivated no tumor progression was evident. Moreover, volume expansion on MR as sign of tumor progression was paralleled by substantially increased amino acid transport ( Fig. 1c and bottom Fig. 2 ). These findings suggest that tumor growth in LGG is maintained by amino acid supply and does not escape towards other metabolic pathways. With regard to identify patients who benefit from treatment the prediction of treatment response in individual patients would have major impact on patient care. Several studies suggested that histological features of LGG (fibrillary astrocytoma versus oligodendroglial tumors) and molecular profiles (e.g. status of loss-of-heterozygosity, LOH, on 1p/19q, methylation of O6-methylguaninemethyltransferase, MGMT) are associated with treatment response and survival. In individual patients, however, treatment response cannot be predicted yet [26, 27] , and molecular markers are not implemented into clinical practice. Actually our data may lead to the concept that individual patient management should be optimized by early response identification in addition to response prediction. We clearly demonstrate the advantage of molecular over structural imaging in LGG particularly with regard to the time window (Fig. 3) . FET PET data may therefore assist to define the maximal duration of chemotherapy. Due to our small sample size we cannot draw final conclusions as to whether the magnitude of PET and MR responses relate to the subsequent clinical course and to the time until tumor progression. This has to be addressed in larger prospective studies. We conclude that the early identification of non-responders will help to minimize any negative impact of chemotherapy on quality of life. Finally, individually optimized treatment will also have economical impact since the costs of PET imaging must be weighted against the expenses of chemotherapy and the management of adverse effects.
